The fate of phenylhydroxylamine in human red cells.
Phenylhydroxylamine added to human red cells under aerobic conditions and in the presence of glucose was partly reduced to aniline. About half the hydroxylamine was recovered as amine after a 2-hr incubation. The aniline, after acetylation, was identified as acetanilide by melting point, Rf-value in TCL as well as UV, IR, and NMR spectroscopy. The fate of the remaining phenylhydroxylamine was followed by use of 14C-labeled phenylhydroxylamine. About 30% of the total radioactivity was bound to hemoglobin or other proteins and about 20% was found in highly polar low-molecular substances which were insoluble in organic solvents. The elucidation of the sites at which phenylhydroxylamine was bound to hemoglobin was complicated by the lability of the bonds. When purified human hemoglobin had reacted with radioactive phenylhydroxylamine, large proportions of the radioactivity bound to hemoglobin were removed by treatment with acid or with PMB for separation of alpha- and beta-chains. The radioactive compound liberated from hemoglobin by acid was found to be aniline. After reaction with phenylhydroxylamine the number of SH groups titrable with PMB was found to be diminished. Pretreatment of hemoglobin with N-ethylmaleimide or PMB decreased the amount of phenylhydroxylamine bound to hemoglobin but did not fully prevent the reaction. Tryptic digestion of hemoglobin after reaction with radioactive phenylhydroxylamine yielded tryptic peptides with lower specific activity than that of hemoglobin. Chymotryptic digestion of the tryptic core yielded a core with specific activity much higher than that of hemoglobin. Fingerprinting of the tryptic or chymotryptic hydrolyzates showed the presence of peptides with high and other ones with low or no radioactivity and of radioactive compounds which did not react with ninhydrin. In the covalent binding of phenylhydroxylamine to globin the SH group beta93 plays an important role, but other yet unknown sites are also reactive.
D000083:Acetanilides / Q000097:blood; D000814:Aniline Compounds / Q000097:blood; D001665:Binding Sites; D004912:Erythrocytes / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006898:Hydroxylamines / Q000097:blood*; D007773:Lactates / Q000494:pharmacology; D008706:Methemoglobin / Q000096:biosynthesis; D009603:Nitroso Compounds / Q000097:blood; D013438:Sulfhydryl Compounds / Q000097:blood
D000083:Acetanilides; D000814:Aniline Compounds; D006454:Hemoglobins; D006898:Hydroxylamines; D007773:Lactates; D009603:Nitroso Compounds; D013438:Sulfhydryl Compounds; D008706:Methemoglobin; D005947:Glucose